Shares of Integra Lifesciences (NASDAQ: IART) plummeted 6.03% in pre-market trading on Thursday following the release of its third-quarter 2025 financial results. The medical device company's performance fell short of Wall Street expectations, primarily due to revenue misses and lowered guidance.

Integra reported Q3 revenue of $402.1 million, representing a 5.6% year-over-year growth but falling short of analyst estimates of $414.2 million. The company cited two supply interruptions as factors impacting its revenue performance. Adding to investor concerns, Integra lowered its full-year revenue guidance to $1.620-$1.640 billion, reflecting both the Q3 performance and updated Q4 assumptions.

Despite the revenue shortfall, Integra did report some positive news. The company's adjusted earnings per share (EPS) of $0.54 beat analyst estimates of $0.43, showcasing a 24.1% increase from the same quarter last year. However, this earnings beat was not enough to offset concerns about the company's top-line growth and future outlook. Integra's Q4 revenue guidance of $420-$440 million also fell below analyst expectations of $457 million, further contributing to the stock's sharp decline.